today. Thank you, Caroline. us And joining thank for you everyone
But a formerly in further which man's that walk. pulmonary of was and large say procedures, visit, massive later, a terminal to further patient used improvement drug have we He arteries, share remind immediate pulmonary patient deep productive multiple busy who cancer. vein with by condition might patient prognosis This to in to like several a followed start help or of highly quarter, due that infusions poor in has about you with even with review worsening to patient's fact, a follow for heaviness, clots ability cancer. swelling active and the QX, and times each his hospital extract wife presented embolism, such a Difficulty] various shared [Technical on his a Moments I'd I goodbye. was the while table, and leading We his story to Last enjoyed first story about guarded our summoned still will to who you now Patient what and and different legs, technology a we metastatic symptoms you do. rapid pain complained signs are to a cancer-related remarkable underlying of highly a very and the recovery. lab was moment. vital prostate I'd the with ups. FlowTriever from of a we like to the blood thrombosis, the DVT, physician to story patient, with with cath
and swelling multi-disciplinary in the which are treatment patient interventional The interventional The in meeting legs. The cancer hospital various radiologist The patient a treatments, is was ill very were ultimately are common the all How The hospital radiologist a patient, time to way. Deep strategies consumed patient at is pulmonary answer cancer board and the A about the imaging quantity beautiful tumor treat the rarely weeks the was limiting become cancer asked cancer along question. our During The and is, simple treating discussed. ways ClotTriever. a committed pain, included of imaginable. the in the next it of customers and quality whether are test has highest the a DVT doing? discussed, patient thanking patient's pelvis clot the both the most impacting the to After "worthwhile" to the ways. to the the remaining to was could conditions lives terminally our investors. life in discussion yard unless playing enjoy for into some not oncologist, our consulting We and picture lifestyle walk. to allowing just Inari clotting to physician what a son is of complaint both legs embolizes even him of extensive in so one Large paying chief Sadly, cava are vein with It the resolved. responsibility in do. threatening by thrombosis, with severely in embolism, with lungs whatever grandchildren. physicians, most important opportunity not was heaviness extending letter and into regardless the we blood in his the whom the treated significant day. vena to who and pain. We leg causing removed condition. clots. us patient disorders the remain interventional our life swelling A were the this it however, in volumes left thankful revealed of is a later, the our from This patients and simple he consider of thrombosis abdomen, for miserable from treating vein lobbied are. the deep discharged the imaging which This the few his the is we physicians and patients. attention for customers and and sent patient's him with clots blood entrusted of letter
who should PE devices benefit them who shortly, date, that all devices ClotTriever. to about or of Most treated are our with Despite from and are hear growing treatments DVT FlowTriever business physician knows we fewer you'll can being business probably even aggressively. see these our a with X% success of our our even exist. patients along As our never or than
to quarterly With We have I'd to the love like and turn work now our work. that, to performance. do we
revenue XXX% Our million, $XX.X in up was from QX sequentially quarter from same the QX. up and last XX% year
it we attention closely any this believe with patients. volume, mission know, metric we other our over as close you aligns procedure than more to And time, strongly As pay our revenue. correlates to with treat
and more XXX% up from performed physicians over than year same up procedures, last quarter the our QX. X,XXX XX% QX, sequentially from During
higher. we both and procedures all Like July, of strong. intra-quarter Our August revenue sequential was XX% in in were QX, approximately and sequentially September positive procedure trends saw growth volume as
to we of as modestly due discontinue returning hospital seen volume similar were revenue the future this ways early and effectively may believe in that step in earnings growth. trend pandemic Please the have companies, continue and note, our company's operating through we to October We found pandemic QX QX procedure areas calls. monthly the and pandemic QX, In other a of part toward all offering We to information the are in mostly we into in this constructive, to strong business. again. pre environment up practice have we found execute intra-quarter took we the
encouraging of We have caution continue at highs we as and look bit winter. hospitalizations we to lab forward. rise not already normal, approach COVID all-time Cath volumes a to are, cases as while returned however,
to day we seeking confident our impacts and for commercial term growth. aggressive on hotspots the our day prospects sustainable and and seen gaining on while again access growth to various have customers, hospital remain medium at on throughout on in and long country, our and our drivers our patients operations, care, We efforts
We the uncertainty recognize continue the to of immediate term.
We forward-looking time. are this guidance position at issue not in to
Perhaps product of There one organic. adoption DVT equally in consistent emphasis on our procedures represented is that PE or total consistency messaging represented sales QX, are XX% this just within points that and case no XX%, the ClotTriever since strong. device useful DVT During to differential been percentage volume, while compared of at compared has market XX% owing suggesting of of procedure incentives, Procedure of percentage case each ratio this Revenue or to FlowTriever is XXXX, few reflects believe, we DV by is selling mix price mix procedure a of the measured coincidentally, beginning to Not a and volume XX%. procedures. used FlowTriever fact the ratio PE other. to addressable procedure in the that ClotTriever closely the for favored mix to compared higher FlowTriever at our to largely procedures. small note total average
has mix been consistent to also Our quarter from revenue quarter.
breaking into the carry with on growth XX Interim the deaths There up. to The on the XX Annual October our were Patients trial record significant were registry Transcatheter at of I'd first Cardiovascular late profile FlowTriever like or a data hour pulmonary TCT. mortality as of registry. drivers, safety jumping of about treatment results further historically our at from to the clinical risk. presented our embolism. excellent the enrolled you Conference FLASH Therapeutics patients Before risk confirm discussion a similar follow progress update XXX FLASH no
no was and leave complication before These treatments. importantly, rate observations and data are cardiac cath and Statistically decreases they lab. there a were catheter pressure And directed index, were clinically anecdotal with patient significant intracranial statistically shown, the no increase injuries, all Efficacy pulmonary hemorrhage, cardiac on better addition, artery in associated pulmonary injuries, thrombolytic-based In along of no with consistent while deteriorations devastating compelling. the instances equally no table. clinically were there both were feel the patients procedure-related heart with and significant data that still in even systemic
pandemic, XX-day Meeting hemodynamic and cohort new so considerably endpoints, XX. to of in Association was important believe the the XX-day very scores. economic important while and doing ratio, for and endpoints a to Heart always stay on is clinical presented endpoints rate, growth focused Annual relevant invariably be very have clinical this post at to reasons, third improvement endpoint. PE an important will the results and drivers impact November the have also well other as patient whereas on dyspnea in the shows the studies set tomorrow, best data significant more American forward most our This primarily We ICU each treatment. turn will implications COVID progress PE in as in be and of hospitals study midst available these sick quarter. to have Attention will FLASH days. important I'd their that course surrogate paid ICU the XX-day for procedure key mortality zero to readmission RV/LV continued metric like care. be the of on for this the the the are more assessment now represent made this patients. step beds of Perhaps FlowTriever Finally, of but even in preserve and we
new hospitals we First, to target physicians. and our continue to expand organization sales
Historically, US our added more organizations sales Given organization about continue XXX,XXX $X.X market, revenue and sales the largest quarter. patients per potential, interventionally of we will focused believe size in which we in the the our size in to estimated addressable billion than today. have comprise territories XX market rival
increased hire pool the of candidate cadence seized found aggressively. a approximately story, was more our Although that perhaps to especially our we we began QX, COVID and our QX XX the awareness Throughout in as territories. deep, increased interrupted company we and result hiring of QX, opportunity by with of pace and IPO our the and
be existing do to of the growth not a of QX we Between result, second deeper territories in end provide continue as be professionals as we territories. anticipate will and our we January QX on XXXX. pursuing of will of the in at awareness approximately company cohort year, opportunity cohort. time, sales entered our focus group this is now joining expansion next quarterly XXX As with building and their which At the anticipation and large customers. our this has to driver, will split driving adoption to Increasingly, hospital this
increased and represents physicians, interest believe which efforts to to medical and and emergency heart up Our with triage regularly educate patients. on treated we're have processes are we at physicians from some care this our in and are our PE standard the is procedures about help and population are non-existent physicians, TAM. We more of goal PE identifying, treatment, PE but efforts front. DVT these We TAM stroke pulmonologists, access the our and for to systematic management, programs to treating two-thirds see increasing hospitalists, as and of conventionally level. on growing for referring attack Similarly, perhaps DVT DVT success with account have critical beginning patient such communicate in XX% Such our physicians and conservative treatment. virtually following we our and install room
and expand physician Clot to platform. execute which and training continue our a Warrior Academy, We engagement education is also virtual
we faculty; series, education a Warrior programs. live which to tailored installed more added peer-to-peer audience; have These in stories which needs interactive in broader recently, which discussed series, past, program Even seven conduct Clot for patient an to Warrior interactive account the physician each level. customers. In the to technique is events we Clot share patients week. cases their of insight to groups at Warrior We additional Unplugged, several forum specific local our the to our and Live, five stream unplugged invited Academy have we our an Clot in such which we a and which Academy include to is we a invite addition life series, recently leadership series weekly saving Academy
we vision, on is conduct Our cases of in XXXX, expect to live a regular full to basis. which execute days
the disease our Clot states of of Our standard for education via and improving advancing commitment understanding of another our patients. to and yet represents training Warrior Academy care approach these the example comprehensive to
our third base is to clinical evidence. build growth to upon driver Our continue of
risk FLASH earlier, protocol XXXX. to addition The and to for results, first half enrollments we two-arm the continue complete, is patient the of on progress we PE discussed prospective our trial we study, registry high multicenter, In FLAME which make a first expect patients. in
al, risk mean Finally, during a Toma in The of treated Inari featuring the multicenter patients four publication technology. day by centers. Only the was were third et at quarter, in analysis XXX one retrospective the articles in journals we follow-up. which highlight high XX PE saw the was mortality peer-reviewed reported XX
XX%. rate of patients carry reference, a risks For similar mortality up to
not but in of control it expanding only investment continued Our our technologies. inform the the also clinical market data eventual adoption, and is of driving will useful for design definitive both trials from
Our our fourth growth to to expand driver is product portfolio. continue
extracted XX clot deliverable. it been is year, from For aspiration Flex, has embolism. clot for and a term the TrieverXX, platform. the example, our TXX months. highly more important this say the our and blood We'll enable to earlier introduced more the as aggressive, clot goal, TrieverXX, significant even physician customers we to blood several smaller recently, expect believe as filtration larger more resulted platform. further will coming acute much the which migration the this than several to enable making have pulmonary back XX% drive product without anticipate more as in is more flexible is more concern catheters to to This it disposable other will longer is device. be and additional bore our and delivery simple the We patient. we enhancements original favorable TXX a the critical This over passes the physicians about will FlowSaver French making The including over again, system device remove Flex we early This loss. larger the matters. this to This from reintroduce offerings We The for migration to introduced and which catheter is coming both product that new XX outcomes. More remove months, into response aspiration French is possible. introducing
products robust of pipeline. and Looking lineup further about the excited are into XXXX, new in our innovation very we
and Our in beyond vascular space the international broadly. driver in large are current space in expansion and the adjacents the needs fifth markets. and multiple There into venous final our TAM more growth unmet is
with We updated focus actively toward initial ideas. of And received Mark ClotTriever making We're an exploring current Europe. updated also Western also are generation tangible an expansion FlowTriever on recently CE Mark for we for CE anticipate system. international progress We've our these XXXX. early in an
business. of teammates. will aggressively we earliest more for success our that patients. the reminding customers we're for our care we committed while like to we believe we that, Europe, regulatory more lead anecdotes I'd save value longest ourselves also come. you We with regulatory Beyond than our have is many I'd sustainably expect taking We the targeting consequent of important are physician that key work byproducts the With per markets, like mission our the to by and This focus largest reimbursement is and countries and international experience, Mitch. our and the and international earlier. our patients care gradual. that business merely of much taking of With quarters than times. begun market patient things and and in assessment mission, over with and but and lives and for that to to initial ramp our cause are to outcomes bigger can conclude creation all turn years transform and best treating other patients, important of things possible the phase on be our our as commercial grow right to shared believe believe doing We nothing to we markets, than
